Summary: Scientific American explores how the future of mental healthcare may be impacted by MAPS’ first Phase 3 trial of MDMA-assisted therapy for PTSD, the results of which were published one week ago in Nature Medicine.
In the article, MAPS Founder and Executive Director Rick Doblin, Ph.D., reflects on the success of the study, stating, “I expected this to work, but the big surprise was how statistically significant it was.”
Originally appearing here.
